Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Aurobindo Pharma...

    Aurobindo Pharma targets to achieve zero debt in three years sans Novartis deal

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-26T09:30:15+05:30  |  Updated On 17 Aug 2021 12:19 PM IST

    In September 2018, the USD three billion drug-maker, Aurobindo Pharma said its US subsidiary entered into an agreement to acquire commercial operations and three manufacturing facilities in America from Sandoz Inc, USA, a Novartis Division, for USD 900 million.


    Hyderabad: Aurobindo Pharma expects to become a debt-free company in the three next years barring the amount it is spending on acquisition of Sandoz products, a senior official of the city-based company has said.


    In September last year, the USD three billion drug-maker said its US subsidiary entered into an agreement to acquire commercial operations and three manufacturing facilities in America from Sandoz Inc, USA, a Novartis Division, for USD 900 million.


    "During the year, we will reduce between USD 150 million to USD 200 million debt, and we have already achieved that..On the long-term front, based on the experience, which we had in the last two or three quarters, and we are targeting to achieve a zero debt in the next three years. That's what we are all seeing on the existing business... without considering Sandoz," Santhanam Subramanian, Aurobindo Chief Financial officer said in a recent earnings call.


    The company's net debt decreased by USD 71 million quarter-on-quarter to USD 522 million at the end of September 2019 against USD 593 million at the end of June 2019.


    The majority of the company's debt is denominated in foreign currency.


    The cash and bank balance were at USD 305 million.


    Replying to query, Narayanan Govindarajan, Aurobindo Pharma's managing director, said they expect Federal Trade Commission's nod for the acquisition of the Sandoz products and three facilities by next month or January.


    The acquisition will add approximately 300 products including projects in development as well as commercial and manufacturing capabilities in the US, complementing and expanding the group's portfolio and pipeline and the portfolio is expected to generate over USD 900 million in sales for the first 12 months after completion of the transaction for Aurobindo, the drug firm had earlier said.


    Read Also: Aurobindo Pharma gets 14 USFDA observations for Pashamylaram facility


    Govindarajan said the company is expecting re-inspection of its three manufacturing facilities, of which one received a warning letter and two others received "official action indicated (OAI)" from the US Food and Drug Administration.


    "The inspection should happen before March or by March-April timeline is what our best estimate is. And we are preparing ourselves to ensure that the inspection goes well," the official said.


    Read Also: Aurobindo Pharma Q2 net profit up by 5 pc to Rs 640 crore

    Aurobindo Pharmaaurobindo pharma debtDebt freeFederal Trade CommissionFTCNovartisOfficial Action IndicatedSandozUS Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok